Cite
MLA Citation
Fengchun Zhang et al.. “Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.” RMD open, vol. 8, no. 1, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100153445632.0x000007